A practical reference on freeze-thaw cycle: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Addiction medicine deals with the treatment of addiction. Aerospace medicine deals with medical problems related to flying and space travel. Biomedical Engineering is a field dealing with the application of engineering principles to medical practice. Clinical pharmacology is concerned with how systems of therapeutics interact with patients. Conservation medicine studies the relationship between human and non-human animal health, and environmental conditions. Also known as ecological medicine, environmental medicine, or medical geology. Disaster medicine deals with medical aspects of emergency preparedness, disaster mitigation and management. Diving medicine (or hyperbaric medicine) is the prevention and treatment of diving-related problems. Evolutionary medicine is a perspective on medicine derived through applying evolutionary theory. Forensic medicine deals with medical questions in legal context, such as determination of the time and cause of death, type of weapon used to inflict trauma, reconstruction of the facial features using remains of deceased (skull) thus aiding identification. Gender-based medicine studies the biological and physiological differences between the human sexes and how that affects differences in disease. Health informatics is a relatively recent field that deal with the application of computers and information technology to medicine. Hospice and Palliative Medicine is a relatively modern branch of clinical medicine that deals with pain and symptom relief and emotional support in patients with terminal illnesses including cancer and heart failure.
==== United Kingdom ==== Phenazepam is a class C drug in the UK. The UK Home Office banned importation of phenazepam on Friday 22 July 2011 while it drafted legislation, released in January 2012 to become law at the end of March 2012. The bill was quashed following advice from the ACMD as it included two non-abusable steroids. There was a new discussion about its fate on April 23, 2012, where it was decided that the bill would be rewritten and phenazepam would still be banned. It was eventually banned on June 13, 2012 as a class C, schedule II drug.
== Biotransformation == After the bite of Bungarus multicinctus the venom enters the bloodstream and enters the circulation and ends up in the central and peripheral nervous system. Since κ-bungarotoxin has a high affinity for nAChRs the venom will target the tissues rich in nAChRs. Together with its prolonged, potentially irreversible binding, there will not be much κ-bungarotoxin available in the bloodstream, but it will remain localized in the central nervous system and ganglia. Unbound nAChRs will only be available through de novo synthesis of these receptors. Though biotransformation of κ-bungarotoxin is not sufficiently researched, the long-chain three-finger toxins (3FTx) family member blocks ion channels on the postsynaptic membrane. Therefore, it is suggested that the toxin works extracellularly, and can thus not be biotransformed by the cytochrome P450 enzymes. κ-Bungarotoxin is a protein and can thus be gradually degraded by enzymes such as peptidases and lysosomes. The result will be smaller peptides and amino acids, which can be used for the synthesis of endogenous compounds. However, since the κ-bungarotoxin's affinity for the neuronal nAChR is very high, not much of the protein can be degraded before the ligand-receptor complex is formed.
A study of transgender Ontario residents aged 16 and over, published in 2016, found that half of them were reluctant to discuss transgender issues with their family doctor. A 2013–2014 nationwide study of young transgender and genderqueer Canadians found that a third of younger (ages 14–18) and half of the older (ages 19–25) respondents missed needed physical health care. Only 15 percent of respondents with a family doctor felt very comfortable discussing transgender issues with them. All Canadian provinces fund some sex reassignment surgeries, with New Brunswick being the last of the provinces to start insuring these procedures in 2016. Waiting times for surgeries can be lengthy, as few surgeons in the country provide them; a clinic in Montreal is the only one providing a full range of procedures. Insurance coverage is not generally provided for the transition-related procedures of facial feminization surgery, tracheal shave, or laser hair removal. And in January 2024, The Alberta government of Danielle Smith announced plans to ban gender affirming surgeries for minors under the age of 18 and hormones and puberty blockers for minors under the age of 16. According to the Canadian Pediatric Society, "Current evidence shows puberty blockers to be safe when used appropriately, and they remain an option to be considered within a wider view of the patient's mental and psychosocial health."
Surveillance studies from 2005 and later show the estimated global incidence is 1–2 cases per million population per year. Sporadic CJD (sCJD) incidence increased from the years 1990–2018 in the UK. Probable or definite sCJD deaths also increased from the years 1996–2018 in twelve additional countries. CJD incidence is greatest in those over the age of 55 years old, with an average age of 67 years old. The intensity of CJD surveillance increases the number of reported cases, often in countries where CJD epidemics have occurred in the past and where surveillance resources are greatest. An increase in surveillance and reporting of CJD is most likely in response to BSE and vCJD. Possible factors contributing to an increase in CJD incidence are an aging population, population increase, clinician awareness, and more accurate diagnostic methods. Since CJD symptoms are similar to other neurological conditions, it is also possible that CJD is mistaken for stroke, acute nephropathy, general dementia, and hyperparathyroidism.
Sources: en.wikipedia.org
== Background == Peptides can serve as sturdy building blocks for a wide range of materials as they can be designed to combine with a range of other building blocks such as lipids, sugars, nucleic acids, metallic nanocrystals, and so on; this gives the peptides an edge over carbon nanotubes, which are another popular nanomaterial, as the carbon structure is unreactive. They also exhibit biocompatibility and molecular recognition; the latter is particularly useful as it enables specific selectivity for building ordered nanostructures. Additionally, peptides have superb resistance to extreme temperature, detergents, and denaturants. The ability of peptides to perform self-assembly allows them to be used as fabrication tools, which will continue to grow as a fundamental part of nanomaterials production. The self-assembling of peptides is facilitated through the molecules' structural and chemical compatibility with each other. The structures formed demonstrate physical and chemical stability. An advantage to using self-assembling peptides to build nanostructures in a bottom-up approach is that specific features can be incorporated; the peptides can be modified to serve specific functions. This approach means the final structures are made from the self-integration of small, simple building blocks. This approach is needed for nanoscale structure, as the top-down method of miniaturizing devices using sophisticated lithography and etching techniques has reached a physical limit.
Many proteins are involved in the process of cell signaling and signal transduction. Some proteins, such as insulin, are extracellular proteins that transmit a signal from the cell in which they were synthesized to other cells in distant tissues. Others are membrane proteins that act as receptors whose main function is to bind a signaling molecule and induce a biochemical response in the cell. Many receptors have a binding site exposed on the cell surface and an effector domain within the cell, which may have enzymatic activity or may undergo a conformational change detected by other proteins within the cell. Antibodies are protein components of an adaptive immune system whose main function is to bind antigens, or foreign substances in the body, and target them for destruction. Antibodies can be secreted into the extracellular environment or anchored in the membranes of specialized B cells known as plasma cells. Whereas enzymes are limited in their binding affinity for their substrates by the necessity of conducting their reaction, antibodies have no such constraints. An antibody's binding affinity to its target is extraordinarily high. Many ligand transport proteins bind particular small biomolecules and transport them to other locations in the body of a multicellular organism. These proteins must have a high binding affinity when their ligand is present in high concentrations, and release the ligand when it is present at low concentrations in the target tissues.
In contrast with EOD, the incidence of LOD has remained unchanged at 0.24-0.26 per 1000 live births in the US. S. agalactiae neonatal meningitis does not present with the hallmark sign of adult meningitis, a stiff neck; rather, it presents with nonspecific symptoms, such as fever, vomiting, and irritability, and can consequently lead to a late diagnosis.
Botulinum toxin produced by Clostridium botulinum (an anaerobic, gram-positive bacterium) is the cause of botulism. Humans most commonly ingest the toxin from eating improperly canned foods in which C. botulinum has grown. However, the toxin can also be introduced through an infected wound. In infants, the bacteria can sometimes grow in the intestines and produce botulinum toxin within the intestine and can cause a condition known as floppy baby syndrome. In all cases, the toxin can then spread, blocking nerves and muscle function. In severe cases, the toxin can block nerves controlling the respiratory system or heart, resulting in death. Botulism can be difficult to diagnose, as it may appear similar to diseases such as Guillain–Barré syndrome, myasthenia gravis, and stroke. Other tests, such as brain scan and spinal fluid examination, may help to rule out other causes. If the symptoms of botulism are diagnosed early, various treatments can be administered. In an effort to remove contaminated food that remains in the gut, enemas or induced vomiting may be used. For wound infections, infected material may be removed surgically. Botulinum antitoxin is available and may be used to prevent the worsening of symptoms, though it will not reverse existing nerve damage. In severe cases, mechanical respiration may be used to support people with respiratory failure. The nerve damage heals over time, generally over weeks to months. With proper treatment, the case fatality rate for botulinum poisoning can be greatly reduced.
Data from high-throughput chromosome conformation capture experiments, such as Hi-C (experiment) and ChIA-PET, can provide information on the three-dimensional structure and nuclear organization of chromatin. Bioinformatic challenges in this field include partitioning the genome into domains, such as Topologically Associating Domains (TADs), that are organised together in three-dimensional space.
Sources: en.wikipedia.org
Since its founding in 1517 on the orders of François I, Le Havre has continued to grow: today it measures 27 km (17 mi) from east to west, about 5 km (3 mi) from north to south with an area of 10,000 hectares (24,711 acres). The last big project called Port 2000 increased the handling capacity for containers. The port provides 16,000 direct jobs to the Le Havre region, to which must be added indirect jobs in industry and transport. With approximately 3,000 employees in 2006, the activities of distribution and warehousing provide more jobs, followed by road transport (2,420 jobs) and handling (2,319 jobs). In 2011, 715,279 passengers passed through the port of Le Havre and there were 95 visits by cruise ships carrying 185,000 passengers. The port expects 110 cruise ship calls in 2012. Created in 1934, the leisure boat harbour of Le Havre is located to the west and is the largest French boat harbour in the Channel with a capacity of 1,160 moorings. Finally, there is a small fishing port in the Saint-François district and a Hawker centre.
=== Metatropic dysplasia === Metatropic means "changing form" and refers to this form of skeletal dysplasia as there is an abnormality in the growth plates. Skeletal changes continue over time and may need surgical intervention to help protect the lungs. Symptoms starting at birth may be mild or can be fatal. There are recognizable features in individuals with this genetic disorder. Some are short stature, narrow chest, "facial features such as a prominent forehead, underdevelopment of the upper jaw, cheekbones and eye sockets (midface hypoplasia), and a squared-off jaw." It is considered a more severe skeletal dysplasia, but is very rare, with the exact number of those affected unknown. Prognosis is largely on a case-by-case basis depending on the severity, and life expectancy may not be impacted unless there are respiratory complications.
So, once they had synthesized L-photo-methionine, the yield was 32%, much higher (by six times) the original synthesis. It was used then (with a protection group Fmoc on the amine) which that product underwent more synthetic steps to study if an amino-acid cross linker and a post-translational modification (PTM) could be introduced to the same protein site specifically to capture a covalent interaction of the amino-acid is dependent on the PTM. PTM's regulate protein-protein interactions that have characteristics that are transient and substoichiometric; making these difficult to detect by standard methods. So, in order to see if it would work, the MH2 domain of Smad2 was used because this signaling protein is known to form stable homo-trimers once they come into contact with receptor-phosphorylated serine residues. Expression protein ligation (known as EPL) was used to synthesize to form Smad2-MH2-CSpSM-photo-Met (1). The product was studied with the cross-linker (photo-Met) against a control protein: HA-MH2-CSpSMpS (this lacks photo-methionine, 2) using SDS-PAGE and western blotting using anti-HA antibody. 1 had generated two major cross-linked species that have molecular weight consistent with a dimer and trimer of Smad2-SH2. Without that cross-linker, the dimer and trimer were barely detected in the non-irradiated 1, and in 2 before and after UV irradiation. Proving that l-photo-methionine can be used with EPL and could be used to determine a transient MH2-MH2 interaction that was dependent on a PTM.
Integrative, multi-locus studies have prompted major revisions of several lichen families and genera. Two examples illustrate the impact of these studies: the re-circumscription of the family Graphidaceae and of the family Ramalinaceae. Graphidaceae—the script lichen family—contains more than 2,000 mostly tropical species. Traditional taxonomy centred on fruiting body shape and a few microscopic characters. A five-locus phylogeny (Rivas-Plata and Lumbsch 2011) showed that many characters had evolved convergently. Slit-like versus rounded discs arose repeatedly, so genera built on those traits mixed unrelated species. Molecular results led to a wholesale recircumscription: several traditional genera were divided and new ones erected to reflect monophyletic clades. For instance, the broad Graphis was split into several smaller, genetically and chemically homogeneous genera. This process was facilitated by projects such as Ticolichen (a tropical lichen inventory project) which combined fieldwork, morphology, chemistry, and DNA sequencing to tackle these revisions. The outcome is a more natural scheme: genera now align with monophyletic clades, even when outwardly dissimilar species must be grouped together. The revision greatly increased recognized genera and species, exposing hidden diversity in tropical crustose lichens. Another major revision, in this case of a mostly temperate/tropical group, was carried out by Kistenich and colleagues (2018) on the family Ramalinaceae. The family had about 40 genera of uncertain affinity, several delimited by only one or two traits.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.